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FEATURED CLINICAL RESEARCH
Mean lesion length was 76.3 ± 38.3 mm; 29.8% of lesions were total occlusions. The
device was successfully utilized in all patients and only 12.3% of lesions required
stenting. At 12 months the primary patency rate was 83.7%, the TLR rate was 7.6%,
85.6% of patients were Rutherford class 0 or 1, and the mean ABI was 0.86 ± 0.15.
QOL and ACD significantly improved post procedure.
Conclusion: Use of a DEB for treatment of femoropopliteal arterial disease resulted
in consistent clinical improvement across multiple endpoints with a low rate of stenting
and TLR.
Efficacy and Safety of Bivalirudin Compared to Unfractionated Heparin
Among Patients Undergoing Balloon Aortic Valvuloplasty: a Two-Center
Registry.
George Dangas, Annapoorna Kini, Jennifer Yu, Mauricio Cohen, Brian O’Neill,
Shyam Poludasu, Christopher Varughese, Evan Jacobs, David Knopf, Vikas Singh,
Jason Kovacic, Robert Pyo, Pedro Moreno, Usman Baber, Roxana Mehran, Samin
Sharma
Background: With transcatheter aortic valve replacement (TAVR) on the horizon,
balloon aortic valvuloplasty (BAV) procedures have increased. A major limitation of
both BAV and TAVR is vascular and bleeding complications, with 30- day rates of
11.0% and 9.3% respectively following TAVR reported in the recent PARTNER trial.
This is partially due to the patient population, and the large caliber arterial access needed
for these procedures. Bivalirudin (BIV) has been shown to reduce bleeding
complications compared to unfractionated heparin (UFH) after PCI. Furthermore, the
“preclosure” technique with a suture-based closure device (VCD) has been reported to
achieve hemostasis after procedures with large caliber arterial sheaths. Clinical outcomes
with BIV, UFH and VCD in BAV procedures have not been previously reported. We
therefore aimed to evaluate the safety and feasibility of BIV vs. UFH in BAV.
Methods: We identified 508 consecutive pts undergoing BAV at 2 tertiary referral
centers. All pts were identified from 1/1/2005 to 12/31/2010. Baseline, clinical, and
angiographic data were extracted by an independent team. All major cardiovascular and
bleeding events were identified, source documented, and adjudicated by an independent
CEC. Clinical follow up was performed up to 30-days post procedure. All emergent
BAV procedures were excluded. Univariate and multivariate logistic regression models
were used to evaluate associations between baseline characteristics, BIV vs. UFH use,
and VCD vs. manual compression use, in reference to in-hospital and 30-day outcomes.
The primary endpoint of the study was incidence of BARC ≥3 bleeding. Major
secondary endpoints included: MACE, stroke, CV and all-cause mortality, as well as
bleeding scales according TIMI major/minor, and VARC definitions.
Results: Complete data on all consecutive patients according to BIV and VCD will be
available for presentation. 
Conclusion: This two center registry comprises the largest clinical data on BAV with BIV
and the first report of BARC, VARC, and TIMI bleeding scale comparison in this arena.
One-Year Outcomes after Implantation of XIENCE PRIME and XIENCE
PRIME Long Lesion stents in Patients with Coronary Artery Disease: Primary
Endpoint Results of the SPIRIT PRIME Multicenter Clinical Trial
Marco A. Costa, Manejeh Yaqub, Dean J. Kereiakes, Robert S. Smith, Xiaohe Yu,
Janah Aji, Louis A. Cannon, John C. Wang, Charles Simonton, Poornima Sood,
Krishnankutty Sudhir2
Background: The XIENCE V everolimus-eluting stent (EES, Abbott Vascular, Santa
Clara, CA) demonstrated superior efficacy and long term safety in the SPIRIT clinical
trials series. The next generation XIENCE PRIME EES includes
2.25 mm diameters and 33 and 38 mm lengths to treat small vessels and long lesions
(LL). The SPIRIT PRIME trial aimed to show clinical equivalence of the XIENCE
PRIME and XIENCE V stents.
Methods: SPIRIT PRIME, a prospective, non-randomized clinical trial with two
separate arms, tested the XIENCE PRIME core sizes and LL (33 and 38 mm) stents.
The primary endpoint is 1-year target lesion failure (TLF; cardiac death, target vessel
myocardial infarction [TV-MI] or clinically indicated target lesion revascularization
[CI-TLR]) compared to pre-specified performance goals based on historical data
according to FDA requirements. The Core Size Registry (CSR) analyzed 401 patients
and the Long Lesion Registry (LLR) 104 patients. Treatment of up to 2 de novo lesions
in different epicardial vessels was allowed. Data were fully monitored and all endpoint
events adjudicated by an independent committee.
Results: There were 447 CSR and 124 LLR lesions treated and a total of 530 XIENCE
PRIME and 105 XIENCE PRIME LL stents implanted. Clinical device success rates
were 98.2% (CSR) and 97.6% (LLR). Female and diabetic subjects were 29.7% and
34.9%, respectively in the CSR and 37.5% and 35.6%, respectively in the LLR. In both
arms, the primary endpoint was met by all analyses. The Table shows 1-year outcomes.
Conclusion: The SPIRIT PRIME study demonstrated 1-year safety and efficacy of the
new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates in core size
and LL cohorts, suggesting clinical equivalence of the XIENCE PRIME stent to
XIENCE V.
SeQuent Please World Wide Registry: Paclitaxel eluting balloon angioplasty in
routine real world practice in a large patient population
Jochen Wöhrle 
Background: The paclitaxel eluting SeQuent Please balloon catheter (B.Braun
Melsungen AG, Germany) has shown to be superior to plain balloon angioplasty for
treatment of in-stent restenosis (ISR) in bare-metal stents (BMS) and in drug-eluting
stents (DES). Furthermore, paclitaxel eluting balloon angioplasty reduced angiographic
and clinical restenosis in de-novo lesions after endothelial progenitor cell capturing
stenting. However, in these trials number of patients was limited and inclusion criteria
were restricted to a pre-defined lesion subset.
Therefore, we performed the SeQuent Please World Wide Registry in order to get the
results of paclitaxel eluting balloon angioplasty in a large sized registry without
limitation to a special patient population.
Methods: 2098 patients with 2359 lesions treated with SeQuent Please paclitaxel
eluting balloon angioplasty were included in 75 centres from 8 countries. Patients are
clinically followed. The primary endpoint is the clinically driven target lesion
revascularization rate (TLR) at 9 month. Secondary clinical endpoints are target vessel
revascularization, vessel thrombosis according to ARC criteria, major adverse cardiac
events as a composite of cardiac death, TLR and myocardial infarction related to the
target vessel.
Results: Patients were included due to treatment of ISR in BMS (38%), ISR in DES
(23%), ISR in DES/BMS (10%) or de-novo lesions (29%). Patients suffered from
STEMI/NSTEMI in 17% and from unstable angina in 39%. Frequency of diabetes
mellitus was high with 35%. Treatment location included LAD (40%), CX artery
(24%), RCA (31%) but also saphenous vein grafts (5%). Balloon length ranged from
10-30mm, balloon diameter from 2.0-4.0mm. Antiplatelet therapy with aspirin was
mainly combined with clopidogrel (96%) but also with prasugrel (4%) and ranged from
3-12 months. Nine months follow-up will be completed in September 2011.
Conclusion: Clinical 9 months data including the primary endpoint (clinically driven
TLR) will be presented for the first time.
The Mechanism Of Stent Thrombosis (MOST) study.
Guido Parodi, Alessio La Manna, Marco Valgimigli, Massimo Fineschi, Vito
Ramazzotti, Benedetta Bellandi, Giampaolo Niccoli, Renato Valenti, David
Antoniucci, Francesco Prati
Background: Stent thrombosis (ST) may occur late after stent implantation, and its
cause remains unknown. The use of Optical Coherence Tomography (OCT) in patients
with ST is a valid approach to understand the impact of stent related features that can
lead to ST. We sought to assess by OCT stent strut coverage and malapposition after
thrombectomy in consecutive patients presenting with ST.
Methods: The Mechanism Of Stent Thrombosis (MOST) Study was a prospective
multicentre non-randomized registry that enrolled 23 (6 subacute, and 17 late or very
late) ST patients between January 2010 and July 2011. The included patients were
matched (1:1) with control subjects who had OCT stent assessment at the same Core
Lab, during the same time period, at the same time interval from stent implantation.
Blinded OCT analyses were done in all cases in a validated core lab (RHR, Rome). The
2 study groups were similar in all the baseline characteristics.
Results: Overall, 16,367 and 13,047 struts were analysed in the ST and in the matched
group, respectively. Patients with ST showed a higher rate of uncovered and
malapposed struts as compared with the control group (table). All patients with ST had
previously discontinued dual antiplatelet therapy (n=14) or showed high residual
platelet reactivity on clopidogrel therapy.
Conclusion: Patients with stent thrombosis showed a higher rate of uncovered and
malapposed stent struts as compared with control subjects. High platelet reactivity
seems a necessary co-factor.
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SAT-TAVI (Single Antiplatelet Therapy for TAVI) study: A Randomized Study
Comparing double to single antiplatelet therapy for Transcatheter Aortic Valve
Implantation
Eugenio Stabile, Giovanni Sorropago, Armando Pucciarelli, Linda Cota, Vittorio
Ambrosini, Lugi Salemme, Marco Agrusta, Paolo Rubino
Background: The use of transcatheter aortic-valve implantation (TAVI) has been
shown to reduce mortality among high-risk patients with aortic stenosis who are not
candidates for surgical replacement. TAVI is performed via the trans-femoral (TF-
TAVI) route as the first choice delivery approach with encouraging results from
randomized trials and worldwide registries. Bleedings and vascular complications are
the most common are common adverse events after TF-TAVI procedure. Available
reports recommend to prescribe double antiplatelet therapy after TAVI. Significant
debate remains, however, with regard to the correlation between the effects of double
or single antiplatelet therapy and ensuing ischemic and hemorrhagic complications.
Aim of this randomized trial is to evaluate safety and efficacy of single vs double
antiplatelet therapy after TAVI. 
Methods: From January 2009 to March 2011, a total of 142 patients in our institutions
underwent TF-TAVI. Patients should have been on aspirin therapy and were randomly
assigned to Thienopiridine Arm (Clopidogrel 75 mg/day or Ticlopidine 250 mg/Bid)
or No Thienopiridine arm.Patients received a detailed clinical assessment and serial
blood testing before and 1 hour, 24 four, 48 eight hours and at discharge after TAVI.
At one month patients underwent a clinical/Echographic follow up visit. Bleedings,
vascular complications, neurologic events valve failures and any other potential adverse
event were classified according to the VARC criteria.
Results: Six months results will be presented at the meeting. Primary endpoint will be
30 days mortality. As secondary endpoints will be considered 30 days bleedings, 30
days MACCE, 6 months valve failures and 6 months neurologic events.
Conclusion: This randomized study will provide a clear indication on the opportunity
to adopt a single vs. double antiplatelet regimen for TAVI.
Hetero Drug-Eluting Stent Implantation (Switch Strategy) for Patients with
Drug-Eluting Stent Restenosis: Final Results From the Prospective Multicentre
Spanish Registry
Fernando Alfonso, Maria J. Perez-Vizcayno, Jaime Dutary, Javier Zueco, Vicens
Marti, Jose M Hernandez, Iñigo Lozano, Jose R Lopez-Minguez, Juan Angel, Angel
Cequier, Raul Moreno, Arturo Garcia-Touchard, Luis Martinez-Elbal, Rafael
Melgares, Cristina Fernandez, Rosana Hernandez
Background: Treatment of patients with drug-eluting stent (DES) in-stent restenosis
(ISR) remains a challenge. We sought to assess the effectiveness of a hetero DES
strategy in patients with DES ISR.
Methods: The RIBS-III study was a prospective, multicentre, study aimed to assess
results of coronary interventions in patients with DES ISR. Hetero-DES implantation
was the recommended strategy. The primary angiographic end-point was minimal
lumen diameter at late follow-up. The main clinical outcome measure was a composite
of cardiac death, myocardial infarction and target lesion revascularization.
Results: 363 consecutive patients with DES ISR from 12 sites in Spain were included.
The hetero-DES strategy was used in 274 patients (75%) and a different therapeutic
modality (no hetero-DES) was used in 89 patients (25%) (homo-DES [n=51], bare-
metal stent [n=9], balloon angioplasty [n=29]). Baseline characteristics were similar in
the 2 groups although time to ISR tended to be shorter and lesion length was longer in
the hetero-DES group. At late angiographic follow-up (median 278 days, 77% of
eligible patients) minimal lumen diameter was larger (1.86±0.7 vs
1.40±0.9 mm, p=0.003) and recurrent restenosis rate lower (22% vs 40%, p=0.008) in
the hetero-DES group. At last clinical follow-up (99% of patients, median 771 days)
event-free survival was superior 77% vs 65%, p=0.039) in the hetero-DES group, as a
result of a lower requirement for target lesion revascularization (19% vs 29%, p=0.06).
After adjustment for confounders using protensity score analysis, minimal lumen
diameter (p=0.001) the restenosis rate (RR 0.41, 95%CI 0.21-0.80, p=0.01) and the
event-free survival (HR 0.56 95%CI 0.33-0.96, p=0.038) remained significantly
improved in the hetero-DES group.
Conclusion: In patients with DES ISR a hetero-DES strategy provides superior late
clinical and angiographic results as compared with alternative interventional
modalities.
2-year results of the subclavian access for TAVI with the CoreValve
bioprosthesis
Anna S. Petronio, Marco De Carlo, Cristina Giannini, Francesco Bedogni,
Francesco Maisano, Federica Ettori, Silvio Klugmann, Arnaldo Poli, Antonio
Mazzocchi, Angelo Ramondo, Gennaro Santoro, Gian Paolo Ussia
Background: Our aim was to assess the safety and efficacy of the subclavian approach
as compared with the transfemoral
Methods: 141 patients who underwent TAVI with The subclavian approach were case
matched with 141 patients who underwent TAVI with the conventional transfemoral
approach.
Results: The subclavian approach was used in 141 patients. . Propensity score analysis
was used to identify and match a control group of patients (n=141) who underwent
TAVI with the conventional transfemoral approach. The rate of peripheral artery disease
was significantly higher in the subclavian vs. femoral group (85.1% vs. 20.6%,
P<0.0001). Device success was 97.9% vs. 96.5% in the subclavian vs. femoral groups,
(P=0.47), with intraprocedural mortality of 1.4% vs. 0.7% (P=0.56). The most common
in-hospital complications were a new left bundle branch block (32.6% vs. 35.5%,
subclavian vs. femoral, P=0.61), and the need for pacemaker (24.1% vs. 23.4%,
P=0.88). The rate of acute renal failure (stage III) was higher in the femoral approach
(5.3% vs. 14.3%, P=0.02 subclavian vs. femoral). The incidence of major and minor
vascular complications were similar in the two groups of patients (1.4% vs. 4.3%,
P=0.15 and 12.1% vs. 9.9%, P=0.56 subclavian vs. femoral) with only two specific
serious complications for the subclavian access (subclavian dissection). The rate of
suboptimal CoreValve deployment was 13.5% vs. 14.2%, subclavian vs. femoral,
P=0.81. The learning curve for the subclavian approach lead to a lower use of general
anesthesia after the first 4 cases (from 74.4% to 44.9%; P=0.001) without affecting
procedural success and duration. The 30-day combined safety endpoint was 16.3% in
the subclavian group and 19.9% in the femoral group (P=0.43). In the subclavian and
femoral groups, actuarial survival was 82.8±3.5% vs. 83.3±3.4% (P=0.92), freedom
from cardiac death was 89.1±2.8% vs. 92.5±2.2% (P=0.36), and freedom from
combined safety endpoint was 83.9±3.8% vs. 78.7±4.2% (P=0.97).
Conclusion: The subclavian approach is a feasible and safe option for TAVI, providing
excellent procedural success and low in-hospital complication rates.
Activity of Platelets after Inhibition and Cardiovascular Events: Drug Eluting
Stent Implantation in Patients with Acute Coronary Syndrome Optical
Coherence Tomography Study: The APICE-OCT Study
Antonio Colombo, Alaide Chieffo, Guido Parodi, Ciro Indolfi, Bernhard Reimers,
Gill Louise Buchanan, Renato Valenti, Annalisa Mongiardo, Francesco Versaci,
Filippo Figini, Angela Migliorini, Carmen Spaccarotella, Salvatore Sacca’, Azeem
Latib, Renato Bianchi, Andrea Pacchioni, Angela Ferrari, David Antoniucci
Background: It has been reported that exposed stent struts are more frequent with first
generation drug eluting stent (DES). To our knowledge, no study has investigated the
rate of exposed (without neointimal coverage) stent struts in new generation DES in
acute coronary syndromes (ACS).
Methods: All eligible patients admitted to 4 Italian centers with ACS( STEMI,
NSTEMI or ACS with negative troponin) and a clinical indication for culprit lesion PCI
were randomized 1:1 to everolimus-(EES, Promus Element, Boston Scientific, Natick,
MA, USA) or zotarolimus-( ZES, Endeavor Resolute, Medtronic, Minneapolis, MN,
USA) eluting stents. Follow-up with OCT was performed at 6 months. The primary
study endpoint was the rate of exposed stent struts in EES vs.ZES evaluated by OCT.
Secondary endpoints were: the rate of malapposed stent struts, neointimal hyperplasia
(NIH) area and major adverse cardiac events (MACE) at 6 months.
Results: A total of 60 patients were enrolled. 83.3% were male with a mean age of 63.0
± 10.8 years and LVEF 51.7 ± 6.4%. Overall 31.7% of the patients presented with
STEMI, of these 63.2% in the anterior territory. Thrombus containing lesions were
present in 60.0%; in 23.3% of all patients thrombus aspiration was performed.
Glycoprotein IIb/IIIa inhibitors were used in 31.7% of the cases and bivalirudin in 16.7%.
The mean lesion length was 20.1 ± 9.7 mm. At 30-days clinical follow-up there was one
sudden cardiac death which occurred 8 days post index procedure, but no other MACE
reported. Six month MACE in addition to OCT analysis results will be presented.
Conclusion: Primary study end-point as well as secondary study endpoints will be
presented at the Scientific Sessions of TCT. 
Randomized Study to Assess the Effect of Thrombus Aspiration on Flow Area
in ST-Elevation Myocardial Infarction Patients: an Optical Frequency Domain
Imaging Study
Patrick Serruys, Yoshinobu Onuma, Leif Thuesen, Niels Ramsing Holm, Felix
Zijlstra, Robert-Jan van Geuns, Martin Van der Ent, Jean Fajadet, Gerhard Schuler,
Steffen Desch
Background: The use of thrombectomy devices during percutaneous coronary
intervention (PCI) in the setting of acute ST elevation myocardial infarction (STEMI)
has been recently shown to improve angiographic and clinical outcomes. The impact
of thrombus removal on acute luminal dimension is, however, still unclear. Removal
of thrombus before stenting could lead to better stent expansion, larger lumen and less
late malapposition. We hypothesize that primary PCI with thrombectomy will reduce
the thrombus burden, resulting in less intraluminal material and larger flow area than
primary PCI without thrombectomy.
Methods: This study is a prospective, randomized controlled, single blind, multi-centre
clinical study in 140 patients. Patients presenting with STEMI <12 hours from onset
of chest pain are randomized in a 1:1 fashion to either primary PCI with thrombectomy
or without thrombectomy. The primary endpoint is minimal flow area immediately
www.JACC.TCTAbstracts2011
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